Prostatic Neoplasms: Clinical Trials

109 trials for Prostatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

42 completed, 18 unknown, 15 recruiting, 11 active not recruiting. 109 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 1109Completed 42, Unknown 18, Recruiting 15, Active not recruiting 11, Terminated 9, Withdrawn 7, Not yet recruiting 6, Enrolling by invitation 1

Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms

Trials (filtered) newest first · largest first

All 109 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery
Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11 - Prostate Cancer, Castration Sensitive Prostate Cancer
Early Phase 1Not yet recruitingUniversity of Texas Southwestern Medical Center302026-10-012026-08-24
PSMA-Targeting Dual-Target Radiopharmaceuticals for Prostate Cancer Imaging
68Ga-Labeled EphA2/PSMA Dual-Target Radiotracer PET/CT imaging, 68Ga-Labeled ACP3/PSMA Dual-Target Radiotracer PET/CT imaging - Prostate Cancer
Early Phase 1Active not recruitingThe First Affiliated Hospital of Soochow University302026-09-242026-11-12
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
[64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma
Early Phase 1Not yet recruitingLumina Pharmaceuticals Inc402026-09-012026-08-28
The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer
177Lu-FC516 - Prostate Cancer
Early Phase 1RecruitingFindCure Biosciences (ZhongShan) Co., Ltd.132026-08-312026-09-04
Preoperative Semaglutide Prior to Radical Prostatectomy
Semaglutide 2.4 mg - Prostate Cancer
Early Phase 1Not yet recruitingBanner Health202026-07-012026-07-27
First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic Cancer
[177Lu]Lu-DOTA-STR-17126, [68Ga]Ga-DOTA-STR-17126 - Metastatic Breast Cancer, Metastatic Prostate Cancer
Early Phase 1RecruitingIntegrated Haematology and Oncology Network202026-05-282026-06-10
RET-Targeted Molecular Imaging Probes in Prostate Cancer
RET-targeted PET/CT molecular imaging, PSMA-targeted PET/CT imaging - Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Prostate Cancer
Early Phase 1Active not recruitingXiangya Hospital of Central South University502026-04-032026-10-21
Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical Study
Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy - Prostate Cancer
Early Phase 1Not yet recruitingZhongda Hospital942026-04-012026-04-08
The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer
⁶⁸Ga-FC516, ⁶⁸Ga-FC516 and ⁶⁸Ga-labeled prostate cancer-targeting tracer - Healthy Adult, Prostate Cancer
Early Phase 1RecruitingFindCure Biosciences (ZhongShan) Co., Ltd.102026-03-092026-09-09
Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
161Tb-LNC1011 - Prostate Cancer
Early Phase 1Not yet recruitingPeking Union Medical College Hospital152026-01-012026-02-02
Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial
Biopsy of Prostate, Biospecimen Collection, Computed Tomography - Prostate Carcinoma
Early Phase 1RecruitingJonsson Comprehensive Cancer Center302025-11-142026-03-10
Akkermansia Muciniphilia and Metabolic Side Effects of ADT
Apple Cider Vinegar - Prostate Cancer, Metabolic Syndrome
Early Phase 1RecruitingWestern University302025-07-022025-08-20
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
Tirzepatide - Diabetes, Prostate Cancer
Early Phase 1RecruitingM.D. Anderson Cancer Center302025-07-022026-09-25
18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study
18F-rhPSMA-7.3 - Prostate Cancer
Early Phase 1WithdrawnUniversity of Alabama at Birmingham2025-04-302024-09-25
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab) - mCRPC
Early Phase 1Active not recruitingShanghai Changzheng Hospital72025-03-102026-07-23
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
[18F]AlF-PSMA-N5, [18F]F-DCFPyL - Prostate Cancer, PET/CT
Early Phase 1RecruitingAnhui Provincial Hospital302024-12-192025-01-03
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto®) in Patients With Non-curative Metastatic Prostate Cancer
lutetium (177Lu) rhPSMA 10.1 and Pluvicto® - Metastatic Prostate Cancer
Early Phase 1TerminatedBlue Earth Therapeutics Ltd172024-10-312025-09-25
68Ga-NTA-476 Imaging in Prostate Cancer
68Ga-NTA-476 - Prostate Cancer
Early Phase 1CompletedMelbourne Theranostic Innovation Centre102024-09-132025-09-25
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
68Ga-AAZTA-NI-093 - Prostate Cancer (Adenocarcinoma)
Early Phase 1UnknownFirst Affiliated Hospital of Fujian Medical University102024-09-012024-09-25
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
P17-079, P16-093, or P15-041 PET/CT - Metastatic Prostate Cancer (mPC)
Early Phase 1Enrolling by invitationPeking Union Medical College Hospital402024-09-012025-03-07

Showing 20 of 109. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (11)  ·  Neoplasm Metastasis (6)  ·  Neoplasms (6)  ·  Ovarian Neoplasms (4)  ·  Pancreatic Neoplasms (4)  ·  Urinary Bladder Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Colonic Neoplasms (3)  ·  Colorectal Neoplasms (3)  ·  Lung Neoplasms (3)  ·  Uterine Cervical Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Carcinoma, Renal Cell (2)  ·  Diabetes Mellitus (2)

Broader conditions

Genital Diseases (109)  ·  Genital Diseases, Male (109)  ·  Genital Neoplasms, Male (109)  ·  Male Urogenital Diseases (109)  ·  Neoplasms by Site (109)  ·  Prostatic Diseases (109)  ·  Urogenital Diseases (109)  ·  Urogenital Neoplasms (108)  ·  Neoplasms (103)  ·  Breast Diseases (11)  ·  Skin Diseases (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Female Urogenital Diseases (9)  ·  Female Urogenital Diseases and Pregnancy Complications (9)

Interventions

Magnetic Resonance Spectroscopy (9)  ·  gallium 68 PSMA-11 (8)  ·  2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (4)  ·  Specimen Handling (4)  ·  Positron Emission Tomography Computed Tomography (3)  ·  2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (2)  ·  68Ga-DKFZ-PSMA-11 (2)  ·  Abiraterone Acetate (2)  ·  HhAntag691 (2)  ·  Radiation (2)  ·  Standard of Care (2)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (2)  ·  bicalutamide (2)  ·  enzalutamide (2)  ·  130-nm albumin-bound paclitaxel (1)

Sponsors

Jonsson Comprehensive Cancer Center (6)  ·  Mayo Clinic (6)  ·  Peking Union Medical College Hospital (5)  ·  Anhui Provincial Hospital (4)  ·  National Cancer Institute (NCI) (4)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4)  ·  First Affiliated Hospital of Fujian Medical University (3)  ·  M.D. Anderson Cancer Center (3)  ·  University of Wisconsin, Madison (3)  ·  Affiliated Hospital of Jiangnan University (2)  ·  FindCure Biosciences (ZhongShan) Co., Ltd. (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Johns Hopkins University (2)  ·  Northwestern University (2)  ·  University of Colorado, Denver (2)

Countries

United States (69)  ·  China (22)  ·  Australia (3)  ·  Canada (3)  ·  United Kingdom (3)  ·  Netherlands (2)  ·  Denmark (1)  ·  Georgia (1)  ·  Jamaica (1)  ·  Pakistan (1)  ·  Spain (1)

Top investigators

Chunjing Yu (3)  ·  Qiang Xie (3)  ·  Jingsong Zhang, M.D., Ph.D. (2)  ·  Misop Han, M.D., M.S. (2)  ·  Rahul Aggarwal, MD (2)  ·  Adriana Coletta (1)  ·  Allan Pantuck, M.D. (1)  ·  Ashley E Ross (1)  ·  Benjamin Franc, MD (1)  ·  Celina Shirazipour, PhD (1)  ·  Christos Kyriakopoulos, MD (1)  ·  Dan Pryma, MD (1)  ·  Daniel Song, M.D. (1)

Results publications

PMID 21233180, PMID 27826729, PMID 28806263, PMID 28894899, PMID 29180633, PMID 29602821, PMID 32466781, PMID 33568190, PMID 36358643, PMID 37914976, PMID 38104131, PMID 38782459, PMID 39136560, PMID 39254446, PMID 39928105, PMID 40177325, PMID 41698328, PMID 41759531, PMID 41833067

NIH funding

P30CA015083 (2), N01CM37120 (1), P30CA006516 (1), P30CA006973 (1), P30CA042014 (1), P30CA060553 (1), P30CA072720 (1), R01CA151395 (1), R01CA211150 (1), R01CA214554 (1), R01CA218547 (1), R01CA238379 (1), R01CA300053 (1), R01EB017449 (1), R44CA275590 (1)